You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

ADVANCING TRANSLATIONAL RESEARCH FOR BIOMEDICAL INNOVATION

More than a decade ago, the NIH Roadmap and the FDA Critical Path Report brought significant public attention and new programmatic efforts to advance translational research as the bridge between the promise of bioscience discoveries and the advancement of new biomedical innovations to improve the lives of patients. Of particular importance for accelerating translational research and overcoming the challenging environment for bioscience innovation is advancing collaborations between industry and academia as a means to both improving R&D productivity and reducing the costs of translating discoveries into new medical products.

The call for greater industry-academia partnerships reflects the unique nature of bioscience innovation when compared to other industrial sectors. For instance, not only is there a greater commitment by the bioscience industry to conduct internal R&D, there is also existing close ties between industry, clinical care, and academic communities due to the necessary interface of “bench and bedside” required for biomedical innovation to move forward.

It is particularly fitting for BIO, the world’s largest biotechnology-focused trade association representing both industry and academic institutions, to take the lead in assessing the volume of activity and trends in industry-university collaborations that are critical for accelerating translational research.

This first-ever measurement of the extent of current industry-academic collaborations considers both the rich environment of engagement and the contribution between industry and academic partners across the four stages that all translational research must pass through in bringing new treatments to patients—basic and applied, technology development, clinical trials, and new product launch.

 

Download the full report

Read the press release